Ozbalak, M. Et Al. 2021. Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21 .

Ozbalak, M., Akay, O. M., PEHLİVAN, M., Yildiz, B., UZAY, A., Yigenoglu, T. N., ... ELVERDİ, T.(2021). Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21.

Ozbalak, Murat Et Al. "Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21, 2021

Ozbalak, Murat Et Al. "Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21, 2021

Ozbalak, M. Et Al. (2021) . "Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21.

@article{article, author={Murat Ozbalak Et Al. }, title={Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2021}